Delayed progression to AIDS in volunteers treated with long-term HIV-1 Immunogen (REMUNE) therapy in Thailand

HIV Medicine
W ChantratitaV Churdboonchart

Abstract

To observe the long-term effects of an immune-based therapy HIV-1 Immunogen (REMUNE; Immune Response Corp., Carlsbad, CA, USA) as a first course of treatment designed to sustain the immune system and thus delay the initiation of therapy with antiretroviral drugs and/or delay disease progression. In this open-label, multi-institute extended phase II P2101B study, disease progression, CD4 and CD8 T-cell counts, HIV-1 RNA levels, and genotypic antiretroviral drug resistance were examined in 223 asymptomatic HIV-1-infected Thai volunteers receiving REMUNE every 12 weeks over 132 weeks. A subset of subjects was randomly selected by the physicians to receive antiretroviral drugs for 10 months. Patients treated with REMUNE demonstrated a low rate of clinical disease progression (0.72 per 100 person-years), higher CD4 and CD8 T-cell counts, higher body weight before and after treatment in the same patient, and stable viral load with no serious adverse events. We found no genotypic evidence of drug resistance in subgroups of patients on REMUNE monotherapy or REMUNE plus antiretrovirals (ARTs). This Thai study, like previous US and European studies, confirms that therapeutic immunization of HIV-infected volunteers modifies disease progre...Continue Reading

References

Mar 1, 1990·Journal of Clinical Microbiology·R BoomJ van der Noordaa
Jan 1, 1995·Clinical Imaging·J FarmanH Rotterdam
May 29, 1998·International Journal of Epidemiology·S G WannametheeP Phanuphak
Oct 24, 2001·HIV Clinical Trials·W SukeepaisarncharoenR B Moss
Nov 28, 2001·JAMA : the Journal of the American Medical Association·R S HoggJ S Montaner
Apr 19, 2003·Journal of Clinical Microbiology·Daniel R KuritzkesDean L Winslow
Sep 27, 2003·HIV Medicine·A PozniakUNKNOWN BHIVA Writing Committee BHIVA Executive Committee
Aug 11, 2005·Current HIV/AIDS Reports·Kristen Marks, Roy M Gulick

❮ Previous
Next ❯

Citations

Aug 11, 2005·Current HIV/AIDS Reports·Yves Lévy
Aug 6, 2005·Autoimmunity Reviews·Aldar S Bourinbaiar, Rivka Abulafia-Lapid
Apr 13, 2007·Journal of Immune Based Therapies and Vaccines·Gareth A D HardyFrances M Gotch
Jun 9, 2016·Expert Opinion on Biological Therapy·Gina M Graziani, Jonathan B Angel
Apr 29, 2011·Journal of Women's Health·Olga Villar-LoubetStephen Weiss
Jan 1, 2006·Current Opinion in HIV and AIDS·Sonya L Heath, J Michael Kilby
Jul 20, 2005·Expert Review of Vaccines·Aldar S Bourinbaiar, Rivka Abulafia-Lapid
Mar 15, 2006·Journal of Immunotherapy·Glenn A Van den BoschViggo F I Van Tendeloo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.